Introducing a New Biomarker Named R2 *‐ BOLD‐MRI Parameter to Assess Treatment Response in Osteosarcoma

Autor: Chu Hyun Kim, Ji Hyun Lee, Ji Won Lee, Eunju Kim, Sang‐Hee Choi
Rok vydání: 2021
Předmět:
Zdroj: Journal of Magnetic Resonance Imaging. 56:538-546
ISSN: 1522-2586
1053-1807
DOI: 10.1002/jmri.28023
Popis: While histologic response to neoadjuvant chemotherapy (NChT) is the major prognostic factor for osteosarcoma treatment, evaluating that response is difficult.To evaluate the feasibility of the blood oxygen level-dependent (BOLD) technique to assess the response to NChT.Prospective.Twelve patients with osteosarcoma undergoing NChT.3 T; T2*-weighted BOLD, dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) (b values of 0, 400, and 1400 seconds/mmExamination was performed before treatment (first), after each cycle of treatment (second and third). At each time point, spin dephasing rates (R2*) from BOLD magnetic resonance imaging (MRI), parameters from DCE-MRI (volume transfer constant [KWilcoxon's signed rank test, Spearman's correlation coefficient (ρ) were used. A P-value of0.05 was considered statistically significant.The difference and relative difference of the R2* values between the first/third MRIs in the extraosseous portion were statistically significant. Only the differences in the kThe R2* from the BOLD MRI technique could be a useful biomarker for evaluating treatment response in osteosarcoma treated with NchT.5 TECHNICAL EFFICACY: Stage 2.
Databáze: OpenAIRE
Externí odkaz: